Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.8% – Here’s Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Free Report) traded down 4.8% on Monday . The company traded as low as $6.44 and last traded at $6.55. 4,844,177 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 14,941,520 shares. The stock had previously closed at $6.88.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on RXRX shares. KeyCorp lowered their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.75.

Check Out Our Latest Stock Analysis on Recursion Pharmaceuticals

Recursion Pharmaceuticals Stock Performance

The company has a market capitalization of $2.57 billion, a PE ratio of -4.29 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average is $6.94 and its two-hundred day moving average is $6.98.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the previous year, the firm earned ($0.43) earnings per share. The firm’s revenue for the quarter was up 147.6% on a year-over-year basis. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares in the company, valued at $3,288,380.78. This represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,341 shares of company stock worth $393,490 in the last ninety days. Insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its position in shares of Recursion Pharmaceuticals by 25.7% during the second quarter. Commonwealth Equity Services LLC now owns 44,241 shares of the company’s stock worth $332,000 after purchasing an additional 9,058 shares in the last quarter. Rhumbline Advisers grew its holdings in Recursion Pharmaceuticals by 24.1% during the 2nd quarter. Rhumbline Advisers now owns 281,348 shares of the company’s stock valued at $2,110,000 after buying an additional 54,576 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after buying an additional 2,598 shares during the last quarter. Arizona State Retirement System boosted its position in shares of Recursion Pharmaceuticals by 11.1% during the second quarter. Arizona State Retirement System now owns 47,691 shares of the company’s stock worth $358,000 after acquiring an additional 4,760 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Recursion Pharmaceuticals during the second quarter valued at $246,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Read More

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.